Auxilium to produce AA4500 batches at new facility by end of next year

By Lisa Kerner

Charlotte, N.C., Sept. 27 - Auxilium Pharmaceuticals, Inc. president and chief executive officer Armando Anido said the company was fortunate that its newly leased Horsham, Pa., manufacturing facility came with much of the necessary equipment in place. In addition, a number of employees that previously worked in facility will now work for Auxilium.

With renovations nearly complete, Auxilium looks forward to producing BLA batches of its AA4500 product by the end of 2007.

Anido commented on progress at the facility Wednesday while speaking at the UBS Global Life Sciences Conference in New York.

Anido gave a brief financial overview, highlighting the $43.3 million net proceeds from a recent offering of 5.5 million shares of stock. This should give the company enough cash through at least March 2008, Anido said.

"Our pipeline actually does bring a significant value to us both in the short term and mid term," Anido said.

He added that AA4500, an injectable enzyme for frozen shoulder, Dupuytren's Contracture and Peryonie's Disease, has the potential to be a "company transforming" product.

Testim for low testosterone continues to be a strong driver for the company. Anido said the number of sales representatives for the product has grown to 150 from 94.

Auxilium is developing its TestoFilm as a quick delivery method of testosterone. The product is in U.S. phase 3 trials as well as a European safety study.

Guidance for 2006 includes revenues between $64 million and $68 million and a net loss of $48 million to $51 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.